Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 3/20 | 0.40 |
| ▸ | CBFB | Q13951 | 5/20 | 0.37 |
| ▸ | AMY1A | P0DUB6 | 4/20 | 0.36 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.33 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.33 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.33 |
| ▸ | FOXO1 | Q12778 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17268720 | 0.89 | MAPT (0.39) | CBFBAMY1AFOXO1MEN1NPC1 | |
| SCHEMBL17268676 | 0.89 | AMY1A (0.38) | ALPLCBFBAMY1AFOXO1MEN1 | |
| SCHEMBL17268664 | 0.88 | CBFB (0.45) | CBFBFOXO1NPC1RAB9A | |
| SCHEMBL17268697 | 0.88 | NPBWR1 (0.38) | CBFBFOXO1 | |
| SCHEMBL17268683 | 0.87 | AMY1A (0.49) | CBFBAMY1AFOXO1MEN1NPC1 | |
| SCHEMBL17268669 | 0.87 | CBFB (0.43) | CBFBAMY1AFOXO1MEN1NPC1 | |
| SCHEMBL17268755 | 0.86 | AMY1A (0.42) | CBFBAMY1AMEN1NPC1ALOX15 | |
| SCHEMBL17268690 | 0.86 | CBFB (0.39) | CBFBAMY1APRKAG1PRKAA1PRKAB1 | |
| SCHEMBL17268666 | 0.85 | NPC1 (0.41) | ALPLCBFBMEN1NPC1ALOX15 | |
| SCHEMBL17268711 | 0.85 | CBFB (0.38) | ALPLCBFBAMY1APRKAG1PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951049-B2 | Pyrazole linked benzimidazole conjugates and a process for preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2018-04-24 | — | — | US | disclosed |
| US-20150329527-A1 | PYRAZOLE LINKED BENZIMIDAZOLE CONJUGATES AND A PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329527-A1 | PYRAZOLE LINKED BENZIMIDAZOLE CONJUGATES AND A PROCESS FOR PREPARATION THEREOF | BRDT, MCL1, MGST3 | ALPL 3575/4885CBFB 3736/4885AMY1A 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.